GSGurmukh Singh

Gurmukh Singh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gurmukh Singh has a total of 84 co-authors. Here are the top co-authors by number of shared publications:

  • Roni J Bollag

    Department of Pathology, Medical College of Georgia, Augusta University , Augusta, GA

    9 shared publications
  • Natasha M Savage

    Department of Pathology, Medical College of Georgia, Augusta University , Augusta, GA

    7 shared publications
  • Hongyan Xu

    Department of Biostatistics, Data Science and Epidemiology School of Pub- lic Health at Augusta University 30912 Augusta GA USA

    6 shared publications
  • Roni J. Bollag

    Department of Pathology Medical College of Georgia at Augusta University 30912 Augusta GA USA

    4 shared publications
  • May Ye Mon

    From the Department of Family Medicine (ND, AS, SM, DP, DS); Department of Pathology, Medical College of Georgia at Augusta University, GA (MYM)

    3 shared publications
  • Natasha M. Savage

    From the Department of Pathology, Medical College of Georgia at Augusta University, Augusta (Singh, Savage, Bollag)

    3 shared publications

Latest Publications

  • Communication of newly diagnosed monoclonal gammopathy as a quasi-critical laboratory value

    by Gurmukh Singh, Roni J Bollag, Natasha M Savage, Mei Zheng, Amany Keruakous

  • Open Access

    Serum free light chain concentration and ratio‐based criterion for myeloma‐defining event, in its current version, is untenable

    by Gurmukh Singh

    Summary: Clinical decision‐making based on myeloma‐defining event criteria using thresholds for involved serum free light chain level of 10 mg/dL and ratio of involved to uninvolved light chain of >100 is a poor indicator for the risk of progression to multiple myeloma. Poor performance of this criterion can be attributed to (a) methodological flaws in the publication on which the light chain level and ratio figures are based, (b) failure to apply light chain type‐specific criteria for kappa and lambda chain‐associated lesions, (c) ‘drift’ in the antibody reactivity for free kappa light chains resulting in higher values in more recent testing, (d) lack of high‐sensitivity imaging in earlier studies resulting in inclusion of patients with occult multiple myeloma, and (e) evidence from newer studies showing much lower risk of progression to myeloma than presented initially. The light chain level and ratio‐based criterion for myeloma‐defining event, in its current form, ought to be removed from the International Myeloma Working Group guidelines. The criterion should be revised by collection of prospective data from multiple institutions using standardized patient selection criteria with emphasis on high‐sensitivity imaging studies to exclude occult multiple myeloma patients, subgrouping patients by intact immunoglobulin smouldering multiple myeloma (SMM); light chain SMM; heavy chain and light chain type of lesion; and application of light chain type‐specific levels per gram of monoclonal immunoglobulin, measuring monoclonal light chains. Both static and dynamic measures should be collected, followed by rigorous statistical analysis to identify parameters predicting risk of progression to multiple myeloma in 2 years.


  • Open Access

    Screening for Light Chain Monoclonal Gammopathy of Undetermined Significance: Pseudo Epidemic Based on Current Diagnostic Criteria

    by Gurmukh Singh, Hongyan Xu, Roni J. Bollag

    Background: An abnormal serum free light chain ratio has been promoted as a marker for light chain monoclonal gammopathy, even in the absence of any other evidence of lympho-plasmacytic pathology. The diagnostic ratio has been used primarily to support the diagnosis of kappa light chain monoclonal gammopathy of undetermined significance (MGUS). The recommended diagnostic ratio has varied from > 1.65 to > 3.15. Methods: Serum free light chain values as well as serum and urine immunofixation results were retrieved from medical records for the period of January 1, 2010, to June 30, 2024. Laboratory and clinical data for 4,998 specimens were reviewed to ascertain the presence/absence of monoclonal gammopathy. Results: In patients with no other evidence of lympho-plasmacytic monoclonal disorder: 1) three of seven specimens with κ/λ ratio < 0.25 exhibited monoclonal lambda light chains in urine; 2) in specimens with κ/λ ratio of 1.66 to 2.9, 13 of 547 (2.4%) had monoclonal kappa light chains in urine; 3) in specimens with κ/λ ratio of 3 - 353, ten of 53 (18.8%) demonstrated monoclonal kappa light chains in urine. Conclusions: Diagnosis of patients with a κ/λ ratio of > 3 or 3.15 as having kappa chain MGUS would result in an unsupported diagnosis, pseudo epidemic, of a premalignant lesion in > 80% of instances. The serum free light chain ratio is not a reliable parameter for diagnosing or excluding light chain monoclonal gammopathy. Before a patient is given the diagnosis of a pre-malignant monoclonal disorder, monoclonality of immunoglobulins ought to be documented, or there becomes a risk of generating a “pseudo epidemic” of MGUS diagnoses.


  • Open Access

    Automated detection of free monoclonal light chains by enhanced-sensitivity modified immunofixation electrophoresis with antisera against free light chains

    by Gurmukh Singh, Emily J Saldaña, Jeff Spencer, Roni J Bollag

    Introduction: About one-third of multiple myelomas produce excess free monoclonal light chains. Detection of monoclonal light chains is important for diagnosis, prognosis, and monitoring of such lesions. A previously described method for detection of monoclonal light chains in serum required multiple manual wash steps. Even though the method has sensitivity similar to that of mass spectrometry, the manual wash steps were a hindrance to the method’s widespread use. Methods: To mitigate the laborious nature of the previous method, the SPIFE Nexus instrument (Helena Laboratories) was modified to automate the sample application, electrophoretic separation, antibody application, washing and blotting steps needed for removal of background proteins. Background noise was mitigated by modifying the wash buffer by adding a detergent. This revised automated electrophoresis protocol was tested in parallel with the previously described method. Results: The sensitivity and specificity of the modified method using antisera to free light chains from 2 sources was comparable to the parameters of the previously described method without the need for manual manipulation. Discussion: The automated protocol employing the SPIFE Nexus instrument and incorporating antisera to free light chains is suitable for routine use in clinical laboratories in an automated, enhanced-sensitivity assay for monoclonal light chains with no need for manual manipulation.


  • Open Access

    Screening for monoclonal gammopathy of undetermined significance is contraindicated

    by Gurmukh Singh

    Incidence of multiple myeloma is about 1.8/100 000. About 3%-5% of adults >50 years of age are diagnosed with monoclonal gammopathy of undetermined significance (MGUS). The prevalence is higher if diagnosis is based on an abnormal ratio of serum free light chains. 300-500 people/10 000 get labelled with a diagnosis of this pre-malignant disorder by using faulty criterion of abnormal light chain ratio. Diagnoses based on an abnormal light chain ratio are incorrect in 96% of instances. However, a large number of people are subjected to psychological trauma and financial toxicity by subjecting them to repeated and invasive testing. If strict criteria requiring the presence of a monoclonal immunoglobulin were used, only about 10 people/10 000 may have MGUS and only one person may progress to multiple myeloma in 10 years. Even that one person gains no benefit from an 'early' diagnosis. Thus, there is only harm and no benefit from screening for MGUS.


  • Monoclonal gammopathy

    by Gurmukh Singh


  • Open Access

    Interpretating Normal Values and Reference Ranges for Laboratory Tests

    by Nancy Doles, May Ye Mon, Arika Shaikh, Samantha Mitchell, Disha Patel, Dean Seehusen, Gurmukh Singh

    Laboratory test results drive about 70% of clinical decisions and are important in making diagnosis, prognosis, ruling out conditions, testing for propensity to disease and monitoring the course of illnesses. The requirement for releasing laboratory results to patients has altered the dynamics of doctor patient interaction. Minor variations in laboratory test results that are labeled by the laboratory as low/high/abnormal may cause unwarranted worry to the patients. The number of laboratory results that are outside the “normal range” far exceeds the clinically meaningful abnormal results due to the usually accepted methodology for ascertaining “normal values”/reference ranges, variations in methods of testing at different laboratories, variations due to age, gender, ethnicity, seasonality, and random variations. The usual process for establishing “normal values/reference ranges” entails testing at least 120 healthy individuals in a given age-group, gender, ethnicity, testing method and related health issues. The central 95% of the values is usually adopted as the normal range. This practice, by definition, labels 5% of healthy individuals as having abnormal laboratory results. This review addresses various issues that affect laboratory test results and interpretation of such results. It also addresses doctor and patient concerns about assessing and reporting laboratory results. In addition to reporting normal values along with patient results, it may be useful to include clinical significance of the findings, in simple terms, such as, no immediate concern, warrants discussion with doctor at the next visit, recommend contacting your doctor for further action.


  • Urine Immunofixation Electrophoresis for Diagnosis of Monoclonal Gammopathy: Evaluation of Methods for Urine Concentration

    by May Ye Mon, Obiora Ufondu, Shanee Mortley, Roni J Bollag, Gurmukh Singh

    Examination of urine by immunofixation electrophoresis (UIFE) is one of the tests recommended for screening and monitoring of monoclonal gammopathies, especially multiple myeloma. Unlike the serum free light chain measurement, a positive result on urine immunofixation is diagnostic for monoclonal immunoglobulin light chains. Urine is usually concentrated, generally by membrane filtration, prior to electrophoresis. Alternative methods to membrane filtration for urine concentration were examined. Residual urine specimens submitted for urine protein electrophoresis were concentrated by precipitation of the proteins by ammonium sulfate salt precipitation, precipitation with ethanol and acetonitrile, and by desiccation. The concentrated specimens were subjected to immunofixation electrophoresis using antisera to free light chains (FLC). The results were compared with those from conventional immunofixation electrophoresis using specimens concentrated by membrane filtration. Ammonium sulfate, ethanol, and acetonitrile precipitation results were less than satisfactory. Concentration by desiccation provided results comparable, if not better than, those by membrane filtration and conventional UIFE. The cost of desiccation is minimal compared to more than $5.00/specimen cost of concentration by membrane filtration. The differences in the results with conventional UIFE and the method described here are likely due to (a) variability in the reactivity of different antisera to free monoclonal light chains, and (b) obscuration of monoclonal free light chains by co-migration with intact immunoglobulin monoclonal proteins. Concentrating urine by desiccation for immunofixation electrophoresis is technically simple, inexpensive, and provides results comparable to concentrating by membrane filtration. Using FLC provides a more sensitive assay than using conventional antisera.


  • Open Access

    C-reactive protein and erythrocyte sedimentation rate in inflammatory lesions: Erythrocyte sedimentation rate test is essential in a subset of patients

    by Gurmukh Singh

    Cho et al1 need to be commended for an attempt to reduce unwarranted tests. Their approach of using the Best Practice Advisory is an appropriate method to address the issue. An alternative approach based on a retrospective review suggested that at the first instance in an episode of care, both C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) tests should be done.2 If both are elevated, CRP is recommended for monitoring. In this study 10,554 ESR + CRP tests were evaluated. In 9054 instances, both results were available. The results were concordant (ie, both positive or both negative) in 71.5% of instances. In 511 instances, CRP was normal and ESR was abnormal. In 151 of these, the CRP was 1.0 mg/L or less and ESR was 60 mm/h or more. In 140 instances, sufficient clinical information was available to ascertain the site of lesion, and the results revealed inflammatory lesions in the skin (n = 39), joints (n = 33), bone (n = 27), colon (n = 11), and other sites (n = 10), and in 20 instances, no explanation for the disparity in results could be ascertained. These results were the basis for the recommendation that both tests should be done at the first instance, and if both CRP and ESR are elevated, the lesion be monitored with CRP determination. In patients with abnormal ESR and normal CRP, repeat testing with ESR is recommended to monitor the course of disease.


  • Open Access

    Quantification of Free Immunoglobulin Light Chains in Urine

    by Gurmukh Singh, Thomas Cotter, May Ye Mon, Hongyan Xu, Roni J Bollag

    Background: The serum-free immunoglobulin light chain assay has been recommended as a screening test for monoclonal gammopathy. We evaluated the usefulness of urine free immunoglobulin light concentration for selection of specimens for immunofixation electrophoresis. Methods: Using kits from The Binding Site for Freelite ®, we validated examination of urine for measuring free κ and λ light chains. The results of urine free light chain concentrations were evaluated to ascertain if the results could be used to reduce the number of specimens requiring urine protein immunofixation electrophoresis. Results: In the 515 specimens examined, there was no evidence of monoclonal gammopathy or history of monoclonal gammopathy in 331. Monoclonal κ or λ light chains were detectable in 42 and 30 specimens, respectively. There was history of κ or λ chain associated monoclonal gammopathy in 62 and 50 patients, respectively. In the 38 monoclonal κ positive urine specimens, with light chain data, κ/λ ratio was >5.83 in all specimens. In 27 specimens positive for monoclonal λ light chains, with light chain data, the urine λ/κ ratio was > 0.17 in 24 of 27 specimens and > 0.041 in all specimens. In patients without monoclonal gammopathy all specimens had a κ/λ ratio of >5.83 or λ/κ ratio >0.17. Conclusions: The Freelite ® assay from The Binding Site is suitable for quantification of free light chains in urine. In patients with known history of monoclonal gammopathy, urine immunofixation electrophoresis may be omitted in specimens with κ/λ ratio of <5.83 for κ associated lesions and λ/κ ratio of <0.041 for λ associated lesions. However, the results do not support using this test for first-time urine testing for monoclonal light chains as it is not predictive of positive result, nor does it exclude a monoclonal light chain in urine.